Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio

Reuters

Feb 12

Aprea <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio

Aprea Therapeutics announced significant recent expansions to its global intellectual property portfolio supporting its DNA Damage Response (DDR) oncology pipeline. In 2025, new patents were granted in Australia and Japan, strengthening coverage for its WEE1 and ATR programs. The core patent families are expected to provide exclusivity into 2045, with additional pending applications that could further extend protection. The WEE1 portfolio protects new chemical entities, pharmaceutical compositions, and methods of treating oncology indications, while the ATR program is supported by multiple issued patents and pending applications internationally. Aprea also filed provisional applications in the U.S. in 2025 for macrocyclic DDR target inhibitors and their methods of use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2275224_en), on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610712996"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610712996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610712996?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610712996","market":"nz","top_or_hot":-1,"title":"Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aprea Therapeutics announced significant recent expansions to its global intellectual property portfolio supporting its DNA Damage Response (DDR) oncology pipeline. In 2025, new patents were granted in Australia and Japan, strengthening coverage for its WEE1 and ATR programs. The core patent families are expected to provide exclusivity into 2045, with additional pending applications that could further extend protection. The WEE1 portfolio protects new chemical entities, pharmaceutical compositions, and methods of treating oncology indications, while the ATR program is supported by multiple issued patents and pending applications internationally. Aprea also filed provisional applications in the U.S. in 2025 for macrocyclic DDR target inhibitors and their methods of use.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2275224_en), on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aprea Therapeutics announced significant recent expansions to its global intellectual property portfolio supporting its DNA Damage Response (DDR) oncology pipeline. In 2025, new patents were granted in Australia and Japan, strengthening coverage for its WEE1 and ATR programs. The core patent families are expected to provide exclusivity into 2045, with additional pending applications that could further extend protection. The WEE1 portfolio protects new chemical entities, pharmaceutical compositions, and methods of treating oncology indications, while the ATR program is supported by multiple issued patents and pending applications internationally. Aprea also filed provisional applications in the U.S. in 2025 for macrocyclic DDR target inhibitors and their methods of use.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2275224_en), on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APRE","symbol_name":"Aprea Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL8z4Rw5:1","article_id":"2610712996","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610712996","pubTimestamp":1770862480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aprea Therapeutics announced significant recent expansions to its global intellectual property portfolio supporting its DNA Damage Response  oncology pipeline. In 2025, new patents were granted in Australia and Japan, strengthening coverage for its WEE1 and ATR programs. The core patent families are expected to provide exclusivity into 2045, with additional pending applications that could further extend protection. The WEE1 portfolio protects new chemical entities, pharmaceutical compositions, and methods of treating oncology indications, while the ATR program is supported by multiple issued patents and pending applications internationally. Aprea also filed provisional applications in the U.S. in 2025 for macrocyclic DDR target inhibitors and their methods of use.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APRE":"Aprea Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Aprea Therapeutics在澳大利亚和日本获得新专利，以加强全球DDR癌症治疗组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APRE":0.9},"content_text":"Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio\n    \n\n        Aprea Therapeutics announced significant recent expansions to its global intellectual property portfolio supporting its DNA Damage Response (DDR) oncology pipeline. In 2025, new patents were granted in Australia and Japan, strengthening coverage for its WEE1 and ATR programs. The core patent families are expected to provide exclusivity into 2045, with additional pending applications that could further extend protection. The WEE1 portfolio protects new chemical entities, pharmaceutical compositions, and methods of treating oncology indications, while the ATR program is supported by multiple issued patents and pending applications internationally. Aprea also filed provisional applications in the U.S. in 2025 for macrocyclic DDR target inhibitors and their methods of use.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2275224_en), on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}